CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang City, Hebei Province, 050051, China.
J Pharm Pharmacol. 2011 Mar;63(3):376-84. doi: 10.1111/j.2042-7158.2010.01227.x. Epub 2011 Feb 8.
Pegylated liposome formulations of vinorelbine with prolonged circulation half-life (t½) are desirable. However, DSPE-PEG could affect vinorelbine loading into vesicles due to electrostatic interactions. To resolve this problem, chol-PEG was used to prepare pegylated liposomal vinorelbine and the factors affecting drug loading and plasma pharmacokinetics were investigated.
Vinorelbine was loaded into liposomes using a novel triethylamine 5-sulfosalicylate gradient. The effects of cholesterol and chol-PEG on drug loading were investigated. Pharmacokinetic studies were performed in normal KunMing mice treated with different liposomal vinorelbine formulations. To clarify the effects of chol-PEG on membrane permeability, drug release experiments were performed based on the fluorescence dequenching phenomenon of a fluorescence marker.
In contrast to DSPE-PEG, even at high PEG grafting density (∼ 8.3 mol%), chol-PEG had no effect on vinorelbine loading into HSPC/cholesterol (3 : 1, mass ratio) vesicles. However, for the formulations with low cholesterol content (HSPC/cholesterol 4 : 1), loading efficiency decreased with increasing chol-PEG content. In vivo, the vinorelbine t½ of low cholesterol formulations decreased with increasing chol-PEG content, but for high cholesterol liposomes, the maximum vinorelbine t½ was achieved at ∼ 3 mol% chol-PEG grafting density. The resulting vinorelbine circulation t½ was ∼ 9.47 h, which was greater than that of non-pegylated liposomes (∼ 5.55 h). Drug release experiments revealed that chol-PEG might induce membrane defects and concomitant release of entrapped marker, especially at high chol-PEG density.
Through the investigation of the effects of chol-PEG and cholesterol, an optimum pegylated liposomal vinorelbine formulation with prolonged t½ was achieved. In plasma, the membrane defect induced by chol-PEG may counteract the long circulation characteristics that chol-PEG afforded. When these two opposite effects reached equilibrium, the maximum vinorelbine t½ was achieved.
具有延长循环半衰期(t½)的聚乙二醇化脂质体制剂是理想的。然而,DSPE-PEG 可能会由于静电相互作用而影响长春瑞滨的载药入囊。为了解决这个问题,使用胆甾醇-PEG 来制备聚乙二醇化脂质体长春瑞滨,并研究了影响载药量和血浆药代动力学的因素。
使用新型三乙胺 5-磺基水杨酸梯度将长春瑞滨载入脂质体。研究了胆固醇和胆甾醇-PEG 对载药量的影响。在不同的脂质体长春瑞滨制剂治疗的正常昆明小鼠中进行药代动力学研究。为了阐明胆甾醇-PEG 对膜通透性的影响,根据荧光标记物的荧光猝灭现象进行了药物释放实验。
与 DSPE-PEG 相反,即使在高 PEG 接枝密度(约 8.3mol%)下,胆甾醇-PEG 对 HSPC/胆固醇(3:1,质量比)囊泡中长春瑞滨的载药量没有影响。然而,对于胆固醇含量较低(HSPC/胆固醇 4:1)的制剂,随着胆甾醇-PEG 含量的增加,载药量效率降低。在体内,低胆固醇制剂的长春瑞滨 t½随着胆甾醇-PEG 含量的增加而降低,但对于高胆固醇脂质体,在约 3mol%胆甾醇-PEG 接枝密度时达到最大长春瑞滨 t½。由此产生的长春瑞滨循环 t½约为 9.47 小时,大于非聚乙二醇化脂质体(约 5.55 小时)。药物释放实验表明,胆甾醇-PEG 可能会诱导膜缺陷并伴随包裹标记物的释放,尤其是在高胆甾醇-PEG 密度下。
通过研究胆甾醇-PEG 和胆固醇的影响,实现了具有延长 t½ 的最佳聚乙二醇化脂质体长春瑞滨制剂。在血浆中,胆甾醇-PEG 诱导的膜缺陷可能会抵消胆甾醇-PEG 提供的长循环特性。当这两种相反的效果达到平衡时,达到最大长春瑞滨 t½。